

**Table 2.3. Case-control case-comparison studies of KSHV and PEL**

Reference, study location and period	Characteristics of cases	Characteristics of controls / comparison group	Detection method	Exposure categories	No. of exposed cases	Relative risk* (95% CI)	Adjusted potential confounders	Comments
Parravicini et al (2000)	4 cases of PEL (all HIV +) 15 KS lesions 10MCD	5 biopsies from tonsils and 5 skin biopsies	Imunofisto-chemistry In PEL derived BC-1 BCP-1 and BCBL Cell lines		4/4 vs. “Extralesional normal tissues in the biopsies tested were consistently normal against the KSHV proteins tested”		None	

BM, Bone marrow; IFA, Immunofluorescent assay; MM, Multiple Myeloma; MGUS, Monoclonal gammopathy of undetermined significance; ORF, Open reading frame

\*POEMS: Polyneropathy, organomegaly, endocrinoplasty M-protein skin changes